Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 10862 [2016-04591]
Download as PDF
<![CDATA[
10862
Federal Register / Vol. 81, No. 41 / Wednesday, March 2, 2016 / Notices
Dated: February 25, 2016.
Lorin S. Curit,
Director, Federal Acquisition Policy Division,
Office of Governmentwide Acquisition Policy,
Office of Acquisition Policy, Office of
Governmentwide Policy.
[FR Doc. 2016–04485 Filed 3–1–16; 8:45 am]
BILLING CODE 6820–EP–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below
concerns Childhood Obesity Research
Demonstration 2.0, FOA DP 16–004,
initial review.
SUMMARY: This document corrects a
notice that was published in the Federal
Register on February 10, 2016, Volume
81, Number 27, pages 7123–7124. The
meeting time and date should read as
follows:
Time and Date: 10:00 a.m.–6:00 p.m.,
EDT, March 15, 2016 (Closed).
FOR FURTHER INFORMATION CONTACT: Jaya
Raman, Ph.D., Scientific Review Officer,
CDC, 4770 Buford Highway NE.,
Mailstop F80, Atlanta, Georgia 30341,
Telephone: (770) 488–6511, KVA5@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2016–04591 Filed 3–1–16; 8:45 am]
BILLING CODE 4163–18–P
mstockstill on DSK4VPTVN1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Clinical Laboratory Improvement
Advisory Committee
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
VerDate Sep<11>2014
19:10 Mar 01, 2016
Jkt 238001
announces the following committee
meeting.
Times And Dates: 8:30 a.m.–5:00
p.m., April 13, 2016; 8:30 a.m.–12:00
p.m., April 14, 2016.
Place: CDC, 1600 Clifton Road NE.,
Tom Harkin Global Communications
Center, Building 19, Auditorium B,
Atlanta, Georgia 30333.
Status: Open to the public, limited
only by the space available. The meeting
room accommodates approximately 100
people. This meeting will also be
webcast, please see information below.
Purpose: This Committee is charged
with providing scientific and technical
advice and guidance to the Secretary of
Health and Human Services (HHS); the
Assistant Secretary for Health; the
Director, Centers for Disease Control
and Prevention; the Commissioner,
Food and Drug Administration (FDA);
and the Administrator, Centers for
Medicare and Medicaid Services (CMS).
The advice and guidance pertain to
general issues related to improvement in
clinical laboratory quality and
laboratory medicine practice and
specific questions related to possible
revision of the Clinical Laboratory
Improvement Amendment (CLIA)
standards. Examples include providing
guidance on studies designed to
improve safety, effectiveness, efficiency,
timeliness, equity, and patientcenteredness of laboratory services;
revisions to the standards under which
clinical laboratories are regulated; the
impact of proposed revisions to the
standards on medical and laboratory
practice; and the modification of the
standards and provision of nonregulatory guidelines to accommodate
technological advances, such as new
test methods, the electronic
transmission of laboratory information,
and mechanisms to improve the
integration of public health and clinical
laboratory practices.
Matters For Discussion: The agenda
will include agency updates from CDC,
CMS, and FDA. Presentations and
discussions will include methods for
improving the effectiveness/efficiency
of CLIAC meetings; an overview of the
CMS Advisory Panel on Clinical
Diagnostic Laboratory Tests; laboratory
interoperability including the Office of
the National Coordinator for Health
Information Technology (ONC) policies
and engagement with clinical
laboratories; update on the cytology
workload project; update on laboratory
biosafety in clinical laboratories; and
future CLIAC topics.
Agenda items are subject to change as
priorities dictate.
Webcast: The meeting will also be
webcast. Persons interested in viewing
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
the webcast can access information at:
https://cdclabtraining.adobeconnect.
com/aprilcliac/.
In-Person Attendance Online
Registration Required: All people
attending the CLIAC meeting in-person
are required to register for the meeting
online at least 5 business days in
advance for U.S. citizens and at least 10
business days in advance for
international registrants. Register at:
https://www.cdc.gov/cliac/Meetings/
MeetingDetails.aspx#.
Register by scrolling down and
clicking the ‘‘Register for this Meeting’’
button and completing all forms
according to the instructions given.
Please complete all the required fields
before submitting your registration and
submit no later than April 7, 2016 for
U.S. registrants and March 31, 2016 for
international registrants.
Providing Oral or Written Comments:
It is the policy of CLIAC to accept
written public comments and provide a
brief period for oral public comments on
agenda items whenever possible.
Oral Comments: In general, each
individual or group requesting to make
oral comments will be limited to a total
time of five minutes (unless otherwise
indicated). Speakers must also submit
their comments in writing for inclusion
in the meeting’s Summary Report. To
assure adequate time is scheduled for
public comments, speakers should
notify the contact person below at least
one week prior to the meeting date.
Written Comments: For individuals or
groups unable to attend the meeting,
CLIAC accepts written comments until
the date of the meeting (unless
otherwise stated). However, it is
requested that comments be submitted
at least one week prior to the meeting
date so that the comments may be made
available to the Committee for their
consideration and for public
distribution. Written comments, one
hard copy with original signature,
should be provided to the contact
person listed below, and will be
included in the meeting’s Summary
Report.
Availability of Meeting Materials: To
support the green initiatives of the
federal government, the CLIAC meeting
materials will be made available to the
Committee and the public in electronic
format (PDF) on the internet instead of
by printed copy. Check the CLIAC Web
site on the day of the meeting for
materials: https://wwwn.cdc.gov/cliac/
cliac_meeting_all_documents.aspx.
Note: If using a mobile device to access the
materials, please verify that the device’s
browser is able to download the files from
the CDC’s Web site before the meeting.
Alternatively, the files can be downloaded to
E:\FR\FM\02MRN1.SGM
02MRN1
]]>Agencies
[Federal Register Volume 81, Number 41 (Wednesday, March 2, 2016)]
[Notices]
[Page 10862]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-04591]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below concerns Childhood Obesity Research
Demonstration 2.0, FOA DP 16-004, initial review.
SUMMARY: This document corrects a notice that was published in the
Federal Register on February 10, 2016, Volume 81, Number 27, pages
7123-7124. The meeting time and date should read as follows:
Time and Date: 10:00 a.m.-6:00 p.m., EDT, March 15, 2016 (Closed).
FOR FURTHER INFORMATION CONTACT: Jaya Raman, Ph.D., Scientific Review
Officer, CDC, 4770 Buford Highway NE., Mailstop F80, Atlanta, Georgia
30341, Telephone: (770) 488-6511, KVA5@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2016-04591 Filed 3-1-16; 8:45 am]
BILLING CODE 4163-18-P
